Locally advanced or advanced gastric and colorectal cancers
Conditions
Interventions
Colorectal cancer immunotherapy group:None
Gastric cancer immunotherapy group:None
Colorectal cancer negative control group:None
Gastric cancer negative control group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients pathologically diagnosed with locally advanced or advanced gastric cancer or colorectal cancer; 2.Age 18 years or older, regardless of sex; 3.For patients with locally advanced disease: patients who are planned to receive PD-1/PD-L1 monoclonal antibody-based immunotherapy, or neoadjuvant therapy combining immunotherapy with radiotherapy, chemotherapy, or other treatments; 4.For patients with advanced disease: patients who are planned to receive immunotherapy-based monotherapy or combination therapy; 5.For patients in the control group: patients who receive chemotherapy or molecular targeted therapy only, without relevant immunotherapy, and who are considered by the investigator to meet the observational requirements of this study; 6.Expected survival time of more than 3 months; 7.Ability to cooperate with the collection of study-related data, biological samples, and follow-up; 8.Voluntary participation in this study and provision of written informed consent;
Exclusion criteria
Exclusion criteria: 1.Patients with cognitive impairment, or patients with brain metastases who have clinical symptoms that prevent them from completing questionnaire-based communication; 2.Patients with severe infection or severe dysfunction of major organs, including the heart, liver, or kidneys; 3.Patients with active infection, including viral, bacterial, fungal, or other microbial infections, or other conditions that may affect gut microbiota composition in the short term; 4.Patients with diarrhea, gastrointestinal inflammation, except chronic atrophic gastritis or non-atrophic gastritis, or other infectious lesions; 5.Patients who have used antibiotics within the past 1 month; 6.Other conditions that the investigator considers unsuitable for study enrollment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbial and metabolic features;Treatment efficacy;Survival and prognostic outcomes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety outcomes; | — |
Countries
China
Contacts
Public ContactSun Weijian
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed